Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | PPIB | P23284 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17570887 | 0.89 | RECQL (0.44) | RECQLGAATRPV1HDAC8PPIB | |
| SCHEMBL17570932 | 0.81 | RECQL (0.46) | RECQLTRPV1HDAC8L3MBTL1 | |
| SCHEMBL19656342 | 0.81 | RECQL (0.39) | RECQLGAAHDAC8L3MBTL1 | |
| SCHEMBL18924179 | 0.78 | RECQL (0.36) | RECQLGAAHDAC8 | |
| SCHEMBL17570931 | 0.70 | RECQL (0.47) | RECQLGAAHDAC8L3MBTL1 | |
| SCHEMBL22987343 | 0.68 | RECQL (0.66) | RECQLGAAEPHX2 | |
| SCHEMBL17570950 | 0.68 | RECQL (0.66) | RECQLGAAEPHX2 | |
| SCHEMBL25908042 | 0.68 | RECQL (0.66) | RECQLGAAEPHX2L3MBTL1 | |
| SCHEMBL31589533 | 0.67 | RECQL (0.81) | RECQLGAAEPHX2 | |
| SCHEMBL31589282 | 0.65 | RECQL (0.78) | RECQLGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-3778601-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3189056-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016036801-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885TRPV1 1591/4885 |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885TRPV1 1591/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | RECQL 3762/4885GAA 2127/4885TRPV1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.